-
Hainan Boao Lecheng Partners with Medlive for Medical Tourism and Online Doctor Education
•
The Hainan Boao Lecheng International Medical Tourism Pilot Zone has entered into a strategic partnership with Medlive (HKG: 2192), a Beijing-based clinician-focused medical information service provider. This collaboration aims to fully leverage the strengths of both entities to enhance online doctor education and support a range of medical services. Expanding…
-
HutchMed Ltd Initiates Phase I Clinical Study for SHP2 Inhibitor HMPL-415 in Solid Tumors
•
China-based HutchMed Ltd (NASDAQ: HCM; HKG: 0013) has announced the initiation of a Phase I clinical study for its investigational novel selective allosteric inhibitor, HMPL-415, which targets Src homology-2 domain-containing protein tyrosine phosphatase-2 (SHP2). The trial, aimed at assessing the molecule in general solid tumors, marked its first patient dosing…
-
GenScript Biotech Expands cGMP Manufacturing for Gene and Cell Therapy in Zhenjiang Facility
•
China-based GenScript Biotech Corporation (HKG: 1548) has announced the expansion of its current Good Manufacturing Practice (cGMP) manufacturing capacity at a new facility located in Zhenjiang, Jiangsu province. This move is set to enhance the company’s ability to offer manufacturing services for sgRNA and non-viral DNA payloads, thereby better serving…
-
Jacobio Pharma Secures RMB 150 Million Investment to Advance Pipeline Programs
•
China-based Jacobio Pharma (HKG: 1167) has announced receiving RMB 150 million (USD 20.7 million) in funding from Beijing E-town International Investment & Development Co., Ltd. The investment is designated to support the research and development of the company’s pipeline programs, including the KRAS G12C-targeted glecirasib and other key projects. Jacobio’s…
-
Genesis MedTech Secures Chinese Market Approval for ArtiSential Laparoscopic Surgical Device
•
Singapore-based Genesis MedTech has announced that it has received market approval in China for its ArtiSential articulating laparoscopic surgical device. The device, originally developed by South Korean firm LivsMed, was exclusively licensed to Genesis for distribution and market development in China in a deal that took place in 2021. Innovative…
-
Shanghai Fosun Pharmaceutical Submits Daxibotulinumtoxin A (RT002) for NMPA Approval
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196), a China-based pharmaceutical company, has announced a market approval filing to the National Medical Products Administration (NMPA) in China for its in-licensed daxibotulinumtoxin A for injection (RT002). The drug has been filed for use in adult cervical dystonia, marking a significant step…
-
Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for SHR-1703 Clinical Study
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a China-based pharmaceutical company, has announced receiving approval from the National Medical Products Administration (NMPA) to initiate a clinical study for its anti-interleukin-5 (IL-5) antibody, SHR-1703. The drug candidate is set to be assessed as a treatment for eosinophilic granulomatous polyangiitis, a rare…
-
C-Mer Eye Care Holdings Ltd Partners with Hong Kong Ophthalmologist for Novel Drug Development
•
China-based C-Mer Eye Care Holdings Ltd (HKG: 3309) has announced the establishment of a joint venture with Doctor Dennis Lam, a distinguished ophthalmologist in Hong Kong. The joint venture, valued at a market capitalization of HKD 50 million (USD 6.4 million), is aimed at focusing on the development of innovative…
-
ChengDu ShengNuo Biotechnology Aims to Raise RMB 160 Million for Peptide Drug CDMO Expansion
•
China-based ChengDu Shengnuo Biotechnology Co., Ltd., (SHA: 688117) has announced plans to raise up to RMB 160 million (USD 22 million) through a private placement. The net proceeds from this capital increase are designated for Contract Development and Manufacturing Organization (CDMO) work on innovative peptide drugs, the industrialization of active…
-
Peijia Medical Receives NMPA Approval for DCwire Micro Guide Wire Device in China
•
Peijia Medical Ltd (HKG: 9996), a leading Chinese firm in the neurointerventional field, has announced receiving market approval from the National Medical Products Administration (NMPA) in China for its DCwire micro guide wire device. This milestone marks the company’s 15th neurointerventional product approval in China, highlighting its commitment to advancing…
-
Chime Biologics, Leads Biolabs, and BeiGene Form Strategic Partnership for LAG-3 mAb LBL-007
•
Wuhan-based Contract Development and Manufacturing Organization (CDMO) Chime Biologics has signed a strategic cooperation agreement with Nanjing-based Leads Biolabs and Beijing firm BeiGene Inc., (NASDAQ: BGNE, HKG: 6160). The cooperation focuses on the development and global manufacturing of LBL-007, a LAG-3 monoclonal antibody (mAb). BeiGene’s Acquisition and Global Rights to…
-
Sirnaomics Ltd Partners with Edirna Inc. to Advance RNA Editing Therapy
•
Sirnaomics Ltd (HKG: 2257), a leading company in the field of RNA therapeutics, has announced a strategic partnership with US-based Edirna Inc., a newly launched biotech startup focused on RNA editing therapy. Funding and Licensing Agreement DetailsUnder the terms of the agreement, Sirnaomics is providing start-up funding to support Edirna’s…
-
Sino Biopharmaceutical’s F-star Therapeutics Inks Third Licensing Deal with Takeda for Immunotherapies
•
Sino Biopharmaceutical Ltd (HKG: 1177) has announced a third licensing agreement between its subsidiary, F-star Therapeutics Inc., (NASDAQ: FSTX), and Japan-based Takeda Pharmaceutical Co., Ltd. The agreement facilitates the utilization of F-star’s proprietary wholly human Fcab and tetravalent mAb2 platforms to develop next-generation multi-specific immunotherapies targeting cancer. Joint Research and…
-
3SBio Inc. Receives NMPA Approval for Nalfurafine Tablets to Treat Hemodialysis-Related Pruritus
•
China-based 3SBio Inc. (HKG: 1530) has announced receiving marketing approval from the National Medical Products Administration (NMPA) in China for its nalfurafine orally disintegrating tablets. The drug is used to improve pruritus in hemodialysis patients in situations where existing treatment efficacy is not ideal. This marks the first and only…
-
Tot Biopharmaceutical and GL-Biotech Collaborate on DisacLink Technology for ADC Advancements
•
China-based Tot Biopharma International Co., Ltd (HKG: 1875) has announced a strategic partnership with compatriot firm GL-Biotech in relation to GL-Biotech’s proprietary DisacLink technology. The collaboration aims to achieve technological breakthroughs, jointly develop, improve, and commercialize fixed-point conjugate technology, with both parties engaging in extensive commercial cooperation for the external…
-
Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for Esflurbiprofen Patch Clinical Study
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its esflurbiprofen patch, a generic version of Japan firm Taisho Pharmaceutical’s Loqoa tape. The intended indication for the patch…
-
Biocytogen Pharmaceuticals Enters Antibody License Agreement with Pheon Therapeutics for ADC Development
•
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced an antibody license agreement with Pheon Therapeutics (Pheon), a leading UK-based antibody-drug conjugate (ADC) specialist developing next-generation ADCs for a wide range of hard-to-treat cancers. According to the agreement, Pheon will develop and commercialize an antibody developed using Biocytogen’s proprietary…
-
Nanjing Kati Medical and Leman Biotech Partner to Advance Immune Metabolism Reprogramming in CAR-T Therapy
•
Nanjing Kati Medical Technology Co., Ltd, a China-based company, has entered into a partnership with Leman Biotech Co., Ltd, a clinical-stage immune-metabolism drug developer based in Shenzhen. The collaboration aims to explore the application and translation capabilities of immune metabolism reprogramming technology (Meta 10) in solid tumor CAR-T therapy, with…
-
China’s MofCOM Hosts Symposium with Multinational Corporations, Promises Development Opportunities
•
This week, China’s Ministry of Commerce (MofCOM) convened a symposium attended by representatives from a dozen non-China-based multinational corporations (MNCs). Minister of Commerce Wang Wentao engaged with the attendees, hearing 25 individual suggestions and discussions on current market conditions from companies such as Bayer AG (ETR: BAYN), Novo Nordisk (NYSE:…
